Michael Barbella, Managing Editor06.24.22
Thirona BV and Free Flow Medical Inc. are teaming up to provide clinicians with advanced high-precision tools for treatment planning.
Thirona’s computer-aided quantitative-CT densitometry analysis (QCT) will be provided to pulmonologists in the form of Free Flow Medical's own report called Compass. Specific targeting information will enable bronchoscopic minimally invasive delivery of the FreeFlow Coil to achieve optimum results.
”Free Flow Medical’s FreeFlow Coil System for bronchoscopic lung volume reduction (BLVR) a versatile and personalized lung volume reduction therapy available for COPD patients (designed to be equally effective in heterogenous and homogenous emphysema, regardless of fissure integrity or presence of collateral ventilation). Hence, specific patient data is key to treatment planning,” said Gerard Criner, M.D., chair and professor of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University.
Thirona specializes in high-precision analysis of lung images with Artificial Intelligence (AI), focusing on innovations for personalized treatment of common and rare lung diseases. By working together with medtech and pharmaceutical companies, Thirona combines the latest science and technology to develop solutions that are intuitive for the clinical user and aid medical specialists in their daily tasks.
Thirona’s LungQ software will provide highly accurate quantifications of anatomical volumes and disease distribution to power the Free Flow Medical Compass service for quantitative CT analysis. “Computer-aided, quantitative CT—densitometry analysis (QCT) has proven to be an important part of coil treatment planning which reduces procedure time and enhances implant effectiveness,” said Mark Mathis, CEO and founder of Free Flow Medical. “Thirona provides the most advanced validated software for quantitative-CT-analysis. This collaboration makes it possible for us to provide our customers with the most precise QCT information possible.”
“Closing in on 10 million lung images analyzed and over 180 scientific publications validating our solutions used in over 600 clinics worldwide, we are confident to provide FreeFlow® Coil userswith a highly reliable set of tools, enabling them to deliver best possible patient care,” Thirona Founder and CEo Eva van Rikxoort said.
Based in The Netherlands, Thirona specializes in artificial intelligence for lung image analysis that allows for precise quantification of disease symptoms and contributes to personalized patient treatment. Thirona partners with research institutions and medical companies in their innovation trajectories to enable breakthroughs in treatment development and clinical care. Solutions developed by Thirona support medical professionals in their daily tasks working with thoracic CT-scans (LungQ), chest X-rays (CAD4TB) and retinal scans (RetCAD). Founded in 2014 by van Rikxoort, the company develops deep learning solutions for lung and retinal image analysis. Solutions developed by Thirona are installed in 45 countries worldwide, enabling medical specialists to provide personalized treatment for common and rare lung diseases.
Free Flow Medical Inc. is a privately held medical device R&D and manufacturing company with offices in the United States and Germany. Its medical technology helps physicians treat their patients with advanced and effective minimally invasive procedures. The company has strong expertise in pulmonary and vascular medicine with long established relationships working with the top hospitals and physicians in these fields.
Thirona’s computer-aided quantitative-CT densitometry analysis (QCT) will be provided to pulmonologists in the form of Free Flow Medical's own report called Compass. Specific targeting information will enable bronchoscopic minimally invasive delivery of the FreeFlow Coil to achieve optimum results.
”Free Flow Medical’s FreeFlow Coil System for bronchoscopic lung volume reduction (BLVR) a versatile and personalized lung volume reduction therapy available for COPD patients (designed to be equally effective in heterogenous and homogenous emphysema, regardless of fissure integrity or presence of collateral ventilation). Hence, specific patient data is key to treatment planning,” said Gerard Criner, M.D., chair and professor of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University.
Thirona specializes in high-precision analysis of lung images with Artificial Intelligence (AI), focusing on innovations for personalized treatment of common and rare lung diseases. By working together with medtech and pharmaceutical companies, Thirona combines the latest science and technology to develop solutions that are intuitive for the clinical user and aid medical specialists in their daily tasks.
Thirona’s LungQ software will provide highly accurate quantifications of anatomical volumes and disease distribution to power the Free Flow Medical Compass service for quantitative CT analysis. “Computer-aided, quantitative CT—densitometry analysis (QCT) has proven to be an important part of coil treatment planning which reduces procedure time and enhances implant effectiveness,” said Mark Mathis, CEO and founder of Free Flow Medical. “Thirona provides the most advanced validated software for quantitative-CT-analysis. This collaboration makes it possible for us to provide our customers with the most precise QCT information possible.”
“Closing in on 10 million lung images analyzed and over 180 scientific publications validating our solutions used in over 600 clinics worldwide, we are confident to provide FreeFlow® Coil userswith a highly reliable set of tools, enabling them to deliver best possible patient care,” Thirona Founder and CEo Eva van Rikxoort said.
Based in The Netherlands, Thirona specializes in artificial intelligence for lung image analysis that allows for precise quantification of disease symptoms and contributes to personalized patient treatment. Thirona partners with research institutions and medical companies in their innovation trajectories to enable breakthroughs in treatment development and clinical care. Solutions developed by Thirona support medical professionals in their daily tasks working with thoracic CT-scans (LungQ), chest X-rays (CAD4TB) and retinal scans (RetCAD). Founded in 2014 by van Rikxoort, the company develops deep learning solutions for lung and retinal image analysis. Solutions developed by Thirona are installed in 45 countries worldwide, enabling medical specialists to provide personalized treatment for common and rare lung diseases.
Free Flow Medical Inc. is a privately held medical device R&D and manufacturing company with offices in the United States and Germany. Its medical technology helps physicians treat their patients with advanced and effective minimally invasive procedures. The company has strong expertise in pulmonary and vascular medicine with long established relationships working with the top hospitals and physicians in these fields.
